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Abstract
There have always been challenges concerning tackling knowledge to practice. It is estimated that 85% of the
investment in health research are wasted. Due to low quality, not all systematic review and meta-analysis are
placed at the top of the hierarchy of evidence. Many individual clinical trials do not have the essential standards;
therefore, conducting systematic reviews based on these low-quality individual studies is unreliable as they
cannot be applied in healthcare decision-making and lead to resource waste. To overcome this great issue,
several organizations have been worked hard to improve data extraction from only well-developed individual
studies. However, it is not sufficient.
It is time to stop and look back all years behind. It is time to reconsider our efforts to make the best conclusion in
order to prohibit the huge waste of energy, time, and resources. The old viewpoint “the Beginning from the End”
must be replaced with the new one “the Beginning from the Beginning”. It means, we must do all struggles to
conduct clinical trials in a standard high-quality format from the beginning as much as we could. Although, it does
not seem easy, it might be possible by funding a high discipline, well-respected organization that is engaged in
this critical issue. The supposed organization must define standards, flexible criteria for clinical trials, and all
investigators must perform clinical trials under the supervision of this organization. Providing a considerable
financial resource to grant the researches of the low- and middle-income countries to do clinical trials based on
the designed protocol, considering an independent, high discipline journal for publishing well-conducted clinical
trials regardless of their results, teaching researchers, considering another efficient policy to rank the journals
rather than “impact factor” could help achieve this far-reach goal.
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Introduction
There has always been concern about tackling knowl-
edge to practice, and the scope to which research
knowledge is utilized [1, 2]. Among the sets of
evidence, systematic review and meta-analysis play
key parts in evidence transferring [3], policy formu-
lation, the development of clinical practice guide-
lines, and informing routine decision-making in
clinical practice [4]. Therefore, failure to use their
findings diminishes healthcare competence and com-
promises quality of life [4].
Meta-analysis, a quantitative statistical method
which integrates the results of several independent
studies, plays a key role in evidence-based medicine.
Meta-analysis is placed at the top of the hierarchy
of evidence, in which clinical evidence is ranked
based on the strength of the freedom from various
sorts of biases [5].
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Unfortunately, the uptake of evidence from sys-
tematic reviews has not been consistent [6]. There
are several obstacles to take in evidence from sys-
tematic reviews including those affecting knowl-
edge, attitude and behavior [4].
Upsettingly, despite the growing prominence
of precise guidelines (such as the PRISMA state-
ment [7] and the AMSTAR checklist [8]), as well
as the expanding profile of evidence-based practice
organizations that focus on systematic reviews, the
average quality of systematic reviews in many areas
has not meaningfully improved over time [9, 10] or
has even gone downhill [11]. The evidence-based
practice organizations have not been triumphant at
highlighting the importance of conducting reviews
and reporting them precisely and scrupulously. As a
result, we face a lot of poorly conducted systematic
reviews despite persistent attempts in the opposite
direction [12].
Systematic Review and
Meta-Analysis
Systematic review involves a comprehensive and
detailed search strategy in all available databases
with the aim of reducing bias by identifying, ap-
praising, and synthesizing all relevant studies on a
specific matter [43].
Meta-analysis is conducted to quantitatively an-
alyze the results of the previous researches in or-
der to derive conclusions about that body of re-
search [43].
Stages of Meta-Analysis
Formulating the Review Question
A short and descriptive title consists of unambigu-
ous declaration of participants, interventions, com-
parisons, outcomes and study design (PICOS) should
be presented [13, 14].
Searching for and Including Primary Stud-
ies
An in-depth search for primary studies including
all general and subject-specific databases, hand
search, contact with authors, and pharmaceutical
companies to locate and achieve them should be
performed [15].
The finding of ongoing studies, and studies
awaiting publication could secure the basis for evidence-
based search [16, 17].
Controlling Quality of Evidence
Low-quality individual studies could end in inap-
propriate results in systematic reviews [18].
A sophisticated quality measurement using gen-
eral critical appraisal guides and design-based qual-
ity checklists must be carried out for selected stud-
ies in order to discover heterogeneity, enlighten de-
cisions regarding appropriateness of meta-analysis,
assess the strength of assumptions and make pro-
posals for future research [18].
Data Extraction
The data must be reviewed in terms of size, and for-
mat of each variable and outcome. Data combining,
then, must be considered based on the heterogeneity
or homogeneity [43].
Data Analysis
Before starting any analysis, the investigators must
evaluate the direction, size, homogeneity of effects,
and strength of evidence. The data will be qualita-
tively and quantitatively reviewed. If the data are
not suitable for combination, the results and charac-
teristics of individual studies should be listed in a
descriptive form. Conversely, if the data are proper
to be combined, the quantitative assessment and
analysis should be performed [43].
What are the Problems with
Systematic Reviews and
Meta-Analysis?
Heterogeneity
Any kind of variability among studies included in a
systematic review is called heterogeneity. Clinical
heterogeneity arises from different characteristics
of participants involved in different individual stud-
ies, types and timing of outcome measurements,
and different intervention characteristics that could
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result in significant statistical heterogeneity, inac-
curate summary effects and associated conclusions,
and misleading decision makers, etc. [20].
On the other hand, the methodological hetero-
geneity is predicated upon the study design and risk
of bias [19].
Another kind of heterogeneity being the conse-
quence of clinical and/or methodological diversities
is called statistical heterogeneity which is the vari-
ability in the intervention effects being evaluated in
different studies [19].
Heterogeneity or non-comparability of the ex-
posures/interventions, outcomes and study subjects
in the primary studies is an inherent limitation of
meta-analysis that could interfere with the authen-
ticity or interpretation of the final summary effect
measures. More stringent inclusion/exclusion crite-
ria to improve homogeneity across primary studies
might be helpful, but at the expense of external
generalization and applicability [21].
Bias
Selection Bias
This bias is the consequence of missed studies. A
source of this type of bias is publication bias. As
only 50% of studies conducted have been ever pub-
lished. In addition, statistically significant findings
are more feasible, and earlier to be published than
studies with non-significant findings [21, 22, 23].
Therefore, ignoring the unpublished, statistically
non-significant data will bias a systematic review
toward positive findings [24].
Information Bias
This type of bias occurs during retrieving informa-
tion from individual studies for inclusion in system-
atic reviews. Different effect sizes from the primary
studies could not be probably translated into single
effect size in a correct manner. In fact, small-study
effect is due to the tendency for small trials to show
larger treatment outcomes than large trials [21].
A meta-epidemiological study consisting of 13
meta-analyses of 153 osteoarthritis trials has showed
larger estimated benefits of treatment in small trials
with fewer than 100 patients per trial as compared
with larger trials [25].
In another meta-epidemiological study of 163
meta-analyses, it has been demonstrated that treat-
ment outcomes were larger in the meta-analysis of
all trials than in single most accurate study [26].
Importantly, moderate-size trials are also prone
to larger effect size [27].
Is There Any Solution for the
Above Problems?
All the problems abovementioned have made re-
searchers and organizations to find solution for pro-
ducing much more precise systematic review and
meta-analysis.
Several organizations which are based on evidence-
based practice have been contemplated into this
regard.
The Cochrane Collaboration
The Cochrane Collaboration is the leading resource
for systematic reviews in health care by using high-
quality information, and up-to date assessment of
the effects of health-care interventions based on
predefined methodology in order to minimize the
bias across in all parts of the process [28, 29].
The Joanna Briggs Institute (JBI)
JBI is an international non-for-profit research and
development center within the Faculty of Health
and Medical Sciences at the University of Ade-
laide, South Australia that produces systematic re-
views [30].
The Center for Reviews and Dissemination
(CRD)
CRD based at the University of York concentrates
on generating policy relevant research by synthe-
sizing evidence, assembling and analyzing data, at
least in part, by producing high quality systematic
reviews from multiple research studies [30].
Evidence for Policy and Practice Informa-
tion and Co-Ordinating Centre (EPPI-Centre)
The objective of this center is developing meth-
ods for systematic reviews and research syntheses,
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conducting reviews, supporting others to undertake
reviews, and providing guidance and training in this
area [30].
The AllTrials Campaign
This is a new campaign established to encourage
reporting and registering both ongoing and old clin-
ical trials in order to catch and collect them all
together. The need for such a campaign has been
originated from the fact that only half of clinical
trials are being reported, at least in part, due to
the negative results of clinical trials. Many system-
atic reviews suffer from publication bias. Nobody
knows how much these biases have affected the
decisions for public health during the several past
decades [31].
ClinicalTrial.gov
ClinicalTrials.gov is an easy access web-based re-
source maintained by the National Library of
Medicine (NLM) at the National Institutes of Health
(NIH). ClinicalTrials.gov contains information about
medical studies in human volunteers [32].
Waste of Research, a Serious
Setback
Sholuck entitled the headline in his article, ”The
Paradox of Health Services Research: If It Is Not
Used, Why Do We Produce So Much of It?” [33].
Regrettably, the rate of the uptake of research
evidence in practice is very low, as it is estimated
to take an only 14% of research for an average of
17 years to be translated into practice [34].
Upsettingly, health-care professionals and pol-
icy makers just occasionally use systematic reviews
to guide decision-making [35, 36, 37, 38, 39].
Albeit, not all meta-analysis is placed at the
top of the hierarchy of evidence due to the insuffi-
cient quality. Many individual trials included in the
study do not consist of allocation concealment and
blinding. Conducting systematic reviews based on
the low-quality randomized clinical trials (RCTs)
leads to unreliable results and could not be applied
in decision making for public health [40]. In con-
trast, they waste resources, energy and time. For
instance, a meta-analysis of RCTs evaluating inten-
sive glycaemic control in non-critically ill hospi-
talized patients showed a non-significant reduction
in mortality (relative risk of 0.95 (95% CI 0.72 to
1.25). In most RCTs included in this meta-analysis,
allocation concealment and blinding were not satis-
factory. For this reason, despite the fact of having
five RCTs, such evidence should not be rated high
in any pyramid [40].
Nearly 85% of the investment in health research
are wasted. Unluckily, such a negative sentiment
due to the losses promotes a series of dedication
to compensate such a huge loss. These attempts
just lead to a vicious circle in which the invest-
ment losses keep persisting and are called the sunk
cost fallacy. The attempts by the systematic re-
view communities to extract valid information from
small, poor-quality trials are an example of this
fallacy [41].
More importantly, the abuse of trial participant
humanism is unethical that is not defensible at all [41].
How Can Evidence-Based Practice
Organizations Resolve the
Problem?
Despite the efforts above-mentioned are necessary
and should be satisfying, they are not sufficient at
all. Nearly all the aforementioned organizations
are concerned about registering all clinical trials re-
gardless of their results, selecting the most precise
and least biased clinical trials to produce more valu-
able systematic reviews. It seems that these efforts
could partially cover the huge problems facing the
production of well-conducted systematic reviews.
For example, the recent efforts of the AllTrial Cam-
paign tend to overcome unregistered clinical trials
and, consequently, publication bias. The Cochrane
systematic review, on the other hand, has so far tried
to reduce the bias in systematic reviews by accu-
rately evaluating, reviewing and selecting RCTs.
Now, what about lower-quality clinical trials
which are excluded? What about the huge amount
of cost, energy, and time of all researchers, volun-
teer participants, and funding organizations? What
about the other types of biases which affect the re-
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sults of systematic reviews leading in less precise,
unreliable results that make harms to patients if
come to practice?
How could the effect size, the issues with con-
cealment allocation, blinding, randomization, and
heterogeneity of individual studies be overcome?
It appears that employing many reviewers to
search for, select, and grade the clinical trials in
hope to retrieve at least a part of detriment is not
the best strategy to perfectly use resources [41].
In reality, the current approach which has been
conducted from the end, where all large well-designed
and small less valuable-designed clinical trials have
already been conducted, a lot of energy, resources,
and huge amount of costs have already been uti-
lized, and an enormous number of moments have
already been taken to the beginning, where we had
to retrieve more precise, well-designed clinical tri-
als among the all of those with the huge number
of extra-resource, energy and time has not been
prosperous at all.
Isn’t it the time to think about this drastic prob-
lem much more deeply? Isn’t it the time to stop the
waste of a lot of supplies? How could we have a set
of homogenous clinical trials not in all, at least in
most their aspects? Is there any key for this giant
dilemma?
The answer is YES!
It is absolutely very difficult to reach, at least at
the first glance. However, if we do not attempt now,
we will never reach this goal at all.
First, we have to replace our old perspective
from ”the Beginning from the End” to ”the Begin-
ning from the Beginning” that aids avoiding the
waste of knowledge.
To make the best future for medicine, we need
a very strong, highly disciplined, well-respected
organization being engaged in this critical issue.
The following steps might be helpful to facili-
tate gaining this purpose.
1. Thinking of a supreme organization with the
above characteristics which conducts a rather
flexible, specific, and comprehensive proto-
col for clinical trials, management, supervi-
sion, registration, control, and publishing al-
most all clinical trials across the globe.
2. All the small and large organizations involved
in this subject matter should get together in
order to evaluate the best strategy regarding
this issue.
3. Election should be aimed at choosing one sin-
gle organization or a preponderant committee
as a supreme leader to take this responsibility.
4. Discussing the dilemmas facing clinical trials’
design, operating, reporting, and publishing.
Conclusions
Improving human’s health is the single goal of all
investigations. Reaching this goal and saving time,
energy, and resources as well, need to consider pal-
liative solutions, as well as a curative and basic
elucidation.
Considering a head organization which takes the
responsibility for directorship, management, and
control of all clinical trials based on a standard, de-
signed protocol could be very useful to overcome
many issues. Providing a considerable financial
resource to grant the researches of the low- and
middle-income countries to do clinical trials based
on the designed protocol, considering an indepen-
dent, high discipline journal for publishing well-
conducted clinical trials regardless of their results,
teaching researchers to understand the importance
of doing a well-designed, well-conducted and well-
reported clinical trials, considering another efficient
policy to rank the journals rather than ”impact fac-
tor” could help achieve this far-reach goal.
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